I own phagecocktails.com. I bought it years ago, when most people had never heard the word, because I could already see where this was going. I have not built anything on it yet, and I will be honest about why: I am still working out what the right thing to build is, because the opportunity is so large and so neglected that it is genuinely hard to know where to put the lever. That tension, enormous promise against near-zero attention, is the whole story of phage therapy. So let me lay out the case for why I bought the domain, and why I think bacteriophages are not a billion-dollar idea but a trillion-dollar one.
The number everyone has agreed to ignore
Start with the threat the answer is meant to address. Antimicrobial resistance is not a future problem. In 2019, an estimated 1.27 million deaths were directly attributable to bacterial antimicrobial resistance, and nearly 5 million deaths were associated with it, more than HIV/AIDS and malaria combined. The 2016 O'Neill Review on Antimicrobial Resistance projected that, on current trajectories, resistant infections could kill 10 million people a year by 2050 and cost the world on the order of $100 trillion in cumulative lost output. Ten million deaths a year is roughly one human being every three seconds.
Now hold that number next to the pipeline meant to stop it. There has not been a genuinely new class of antibiotic brought to market for most Gram-negative infections in decades; the discoveries that fueled the twentieth century were largely mined out by the 1980s. The large pharmaceutical companies that once carried antibiotic R&D have, one after another, left the field, because a drug you take for ten days and are told to use as little as possible is a terrible business compared to a drug you take every day for life. We built an entire civilization on antibiotics and then let the factory that makes them rust.
So the rational question is: what do we have that could actually replace or rescue them? And the most honest answer, the one that keeps surfacing every time the science is examined seriously, is bacteriophages.
What phages are, and why they are different
A bacteriophage is a virus that infects bacteria and nothing else. They are the most abundant biological entities on Earth (there are an estimated 10³¹ of them, more than every other organism combined), and they have been waging a four-billion-year war against bacteria with a precision no human-designed drug has ever approached. A phage does not carpet-bomb the body the way a broad-spectrum antibiotic does. It targets a specific bacterial species, often a specific strain, replicates only where its host is present, and disappears when the host is gone. It evolves. When bacteria develop resistance to a phage, the phage can evolve to overcome it: a moving target answering a moving target, which is exactly what a static small molecule can never do.
That specificity is the point, and it is also, as we will see, the reason the money stays away.
This is not theoretical. It has been used for a century.
The strangest thing about phage therapy is that it is not new but genuinely old. Phages were discovered in 1917 by Félix d'Hérelle, and in the Soviet world they never stopped being used. The Eliava Institute in Tbilisi, Georgia, founded in 1923, has treated patients with phage preparations for a hundred years. Poland's Hirszfeld Institute has run phage therapy for decades. While the West, intoxicated by penicillin, walked away, an entire parallel medical tradition kept the practice alive.
And in the West, when antibiotics fail completely, phages keep saving lives one desperate case at a time:
- In 2016, a UC San Diego psychiatrist, Tom Patterson, was dying of a multidrug-resistant Acinetobacter baumannii infection. Out of options, his physician-scientist wife, Steffanie Strathdee, assembled an emergency phage cocktail from labs around the world. He recovered. That case launched IPATH, the first dedicated phage therapy center in North America.
- In 2019, a teenager with cystic fibrosis named Isabelle Carnell-Holdaway, dying of a disseminated Mycobacterium abscessus infection after a lung transplant, was treated with a genetically engineered phage cocktail and recovered, the first such documented case.
- Belgium has built a pragmatic regulatory path through the magistral preparation framework, letting pharmacists compound patient-specific phage preparations on prescription, quietly doing what the rest of the regulatory world claims is impossible.
Every one of these is a compassionate-use story. A person had to be nearly dead, every antibiotic had to fail first, and a small band of researchers had to improvise a treatment by hand.
That is not the profile of a fringe idea that does not work.
That is the profile of a working therapy that no system has been built to deliver.
Where it should be used first: the NICU
If you want to see both the promise and the moral stakes at their sharpest, look at the neonatal intensive care unit.
Premature and critically ill newborns die from infections that should be survivable: bloodstream infections, ventilator-associated pneumonias, and above all the catastrophe of necrotizing enterocolitis (NEC), in which the immature gut is overrun and tissue dies. These are frequently nosocomial, acquired in the hospital itself, and increasingly driven by multidrug-resistant Gram-negative organisms: Klebsiella pneumoniae, Escherichia coli, Enterobacter, Acinetobacter. A neonate has almost no immune reserve and almost no margin. When the antibiotics fail in a NICU, there is very often nothing else, and a child who weighed two pounds and was going to make it does not.
This is precisely where phages belong, and for reasons beyond "we are out of drugs." A broad-spectrum antibiotic given to a newborn does not just fight the pathogen; it incinerates the founding microbiome at the exact moment that microbiome is being established for life, a tradeoff with consequences that follow the child for decades. A phage does the opposite. It removes the one organism that is killing the infant and leaves the developing ecosystem intact. I have written separately about the mechanistic role of nickel in necrotizing enterocolitis; pair that understanding of which organisms drive NEC with a therapy that can surgically remove exactly those organisms, and you have something no antibiotic can offer: lethal precision in the one patient population that can least afford collateral damage.
The NICU is the moral center of this argument. If phage therapy can save the smallest, most vulnerable patients in the building, and the case histories say it can, then the failure to fund its development is not a scientific judgment but a choice.
Follow the money, or rather, follow its absence
Here is the part that should make you uncomfortable.
We have a therapy with a century of clinical use, a mechanism uniquely suited to the defining medical threat of the century, and a string of last-minute rescues when nothing else worked. And the global research funding directed at it is, relative to the size of the problem, a rounding error. There is no Operation Warp Speed for phages. There is no $100 billion moonshot. There are a handful of academic centers, a few small biotechs, some philanthropic grants, and a lot of brilliant people improvising.
Why? The answer is not mysterious, and that is what makes it damning. The market cannot price what it cannot own. Phages are natural entities; a naturally occurring phage is difficult to patent the way a novel molecule is. A phage cocktail tailored to a patient changes composition as resistance evolves, which breaks the entire regulatory model built around a single, fixed, identical-every-time chemical entity. The economics that pulled pharma out of antibiotics pull it ten times harder out of phages: not only is the product used briefly and sparingly, it may not even be ownable. So the capital does not come, the trials do not get funded at scale, the regulatory pathways do not get built, and the therapy that could answer antimicrobial resistance stays locked in compassionate-use limbo while the death toll climbs toward eight figures a year.
I want to be careful here, because the honest version of this is more disturbing than a cartoon villain. I am not claiming a smoke-filled room. I am claiming something worse and more plausible: a set of incentives so misaligned that the system behaves exactly as if there were a coordinated effort to suppress our access to the antibiotic therapies of the future, without anyone ever having to coordinate anything. When you find a structure that reliably starves the most promising answer to a problem that kills millions, you do not need a conspiracy. You need only ask who benefits from the status quo, and notice that the answer is "the people who sell the failing alternative." Decide for yourself what to call that.
Push will come to shove
None of this holds. It cannot. As resistance spreads and the last-line antibiotics fall one by one, the day arrives when a routine infection in an ordinary hospital has no answer, and then another, and then it is not rare. At that point the calculus that kept phages starved inverts overnight, because the alternative to funding them becomes watching people die of paper cuts again. Push comes to shove, and the something they are finally forced to reach for is going to be phages. It is the only thing in the cabinet with the right mechanism.
The countries and institutions that kept the knowledge alive (Georgia, Poland, Belgium) will look prescient. The domains, the cocktails, the manufacturing know-how, the regulatory templates will suddenly be worth more than anyone wanted to admit. This is the part I have been early on, the way I was early on Paleo, on the microbiome, on heavy metals. I am not guessing about whether. I am only telling you about when, and warning you, as I always do, that I am usually too early on the when and never wrong on the what.
The real prize: cocktails built from microbiome signatures
Now the part almost no one is thinking about yet, which is the reason I bought phagecocktails.com specifically.
The future of this is not a single phage against a single bug but phage cocktails: tailored combinations of phages assembled to target a particular patient's particular infection. And the moment you say "tailored to the patient," you should hear the word that defines the next era of medicine: precision.
Here is the synthesis I have been building toward for years. I have spent a decade formalizing microbiome signatures: the condition-specific patterns of which organisms are elevated and which are depleted in a given disease. Now connect that to phage therapy. If you know, from a person's microbiome signature, exactly which taxa are driving their disease, then you know exactly which phages to load into the cocktail. The signature becomes the targeting system; the cocktail becomes the weapon. You are no longer treating "an infection." You are removing, organism by organism, the specific microbial configuration that is making this person sick, and leaving the rest of their ecosystem standing.
That is precision medicine of a kind no one has even put on the roadmap. Not 2030 medicine but 2050 medicine, and it is buildable now, with tools that already exist, the instant someone decides the prize is worth the work. I have dreamed it already. That is why I am calling the trend. That is why I own the domains.
It affects every living thing on the planet: every human, every animal, every agricultural system that antibiotics currently prop up. A therapy that can answer antimicrobial resistance without destroying the microbiome is not a product category but infrastructure for the survival of medicine itself. Call it a billion-dollar idea if you want. You will be off by three orders of magnitude.
If you are funding the future and you would rather hear what is coming from someone with a documented record of calling it early than from a trend report, you know where to find me.